ID: ALA168949

Max Phase: Preclinical

Molecular Formula: C22H30N6O4S

Molecular Weight: 474.59

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCc1nc(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nn12

Standard InChI:  InChI=1S/C22H30N6O4S/c1-5-7-19-23-15(3)20-22(29)24-21(25-28(19)20)17-14-16(8-9-18(17)32-6-2)33(30,31)27-12-10-26(4)11-13-27/h8-9,14H,5-7,10-13H2,1-4H3,(H,24,25,29)

Standard InChI Key:  AIVNVMRJLJHFCU-UHFFFAOYSA-N

Associated Targets(Human)

Phosphodiesterase 5A 5113 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphodiesterase 3 1749 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphodiesterase 4 3344 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphodiesterase 1 671 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphodiesterase 4B 2748 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Phosphodiesterase 1 205 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 474.59Molecular Weight (Monoisotopic): 474.2049AlogP: 1.68#Rotatable Bonds: 7
Polar Surface Area: 112.90Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.93CX Basic pKa: 5.98CX LogP: 0.75CX LogD: 0.72
Aromatic Rings: 3Heavy Atoms: 33QED Weighted: 0.55Np Likeness Score: -1.58

References

1. Haning H, Niewöhner U, Schenke T, Es-Sayed M, Schmidt G, Lampe T, Bischoff E..  (2002)  Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.,  12  (6): [PMID:11958981] [10.1016/s0960-894x(02)00030-6]
2. Haning H, Niewöhner U, Schenke T, Lampe T, Hillisch A, Bischoff E..  (2005)  Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.,  15  (17): [PMID:15993055] [10.1016/j.bmcl.2005.05.090]
3. Antunes JE, Freitas MP, da Cunha EF, Ramalho TC, Rittner R..  (2008)  In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.,  16  (16): [PMID:18656371] [10.1016/j.bmc.2008.07.022]
4. Jansen C, Kooistra AJ, Kanev GK, Leurs R, de Esch IJ, de Graaf C..  (2016)  PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,  59  (15): [PMID:26908025] [10.1021/acs.jmedchem.5b01813]

Source